医学博士，主任医师，2008年于北京大学医学部获肿瘤学博士学位后在北京大学肿瘤医院肝胆胰腺外科工作至今，长期工作于临床第一线，在转移及原发性肝癌、胰腺良恶性肿瘤的诊断、外科切除、围手术期综合治疗以及临床研究等方面拥有丰富的经验。近年来致力于肿瘤微创外科治疗及转移及原发性肝癌术后转移复发研究，并作为主要研究者参与两项国自然面上基金项目。

社会任职：

中国医师协会结直肠肿瘤专业委员肝转移学组委员；

中国抗癌协会肿瘤消融治疗专业委员会委员；

中国抗癌协会肿瘤肝病学专委会委员；

中国医疗保健国际交流促进会转移肿瘤治疗学分会委员；

中国老年学和老年医学学会转化医学分会委员。

代表性成果：

1. Wang HW, X. Yan, L. Wang, M. Zhang, C. Yang, Wei-Liu, K. Jin, Q. Bao, J. Li, K. Wang and B. Xing, Characterization of genomic alterations in chinese colorectal cancer patients with liver metastases, J TRANSL MED 19 (2021), no. 3131.

2.Xu D, Wang H, Bao Q, Jin K, Liu M, Liu W, Yan X, Wang L, Zhang Y, Wang G, Ma Y, Ma Z, Zhang C, Tang J, Wang S, Pang J, Xu T, Wang K, Xing B. The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial. Nat Commun. 2025 Feb 7;16(1):1443

2. Wang HW, K. Jin, J. Li, K. Wang and B. Xing, Postoperative complications predict poor outcomes only in patients with a low modified clinical score after resection of colorectal liver metastases: a retrospective cohort study, UPDATES SURG 74 (2022), no. 5, 1601-1610. （SCI收录 IF：2.692，第一作者）

3. L. Wang, Wang HW, Y. Cui, M. Liu, K. Jin, D. Xu, K. Wang and B. Xing, Sintilimab plus lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: a phase 2 study, FRONT ONCOL 13 (2023), no. 1115109.

4. Wang HW, L. Wang, K. Jin, Q. Bao, J. Li, K. Wang and B. Xing, The prognostic impact of resection margin status varies according to the genetic and morphological evaluation (game) score for colorectal liver metastasis, J SURG ONCOL 124 (2021), no. 4, 619-626.

5. Wang HW, L. Wang, K. Jin, Q. Bao, J. Li, S. Ge, K. Wang and B. Xing, Impact of age of onset on survival after hepatectomy for patients with colorectal cancer liver metastasis: a real-world single-center experience, CURR ONCOL 29 (2022), no. 11, 8456-8467.